Home Alzheimer’s Disease Interim Results from Phase Ib/II CLASSICAL-Lung Study Show Promise in NSCLC

Interim Results from Phase Ib/II CLASSICAL-Lung Study Show Promise in NSCLC

Updated interim results from CLASSICAL-Lung, a phase Ib/II study of pepinemab in combination with avelumab (Bavencio) showed promise in patients with non-small cell lung cancer (NSCLC), according to a presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, held from April 27-28, 2020.1

The multi-center, open-label study is designed to evaluate the combination in 62 patients with advanced stage (IIIB/IV) NSCLC, including immunotherapy-naïve patients and those whose tumors progressed during or following chemotherapy.2 The data presented at AACR builds upon results previously presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2019.3

“Pepinemab is a humanized IGG4 antibody which binds to and blocks SEMA4D activity,” Jonathan W. Goldman, MD, from UCLA in Santa Monica, California, said in a poster…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Podcast Episode Interviewing Brain Cancer Fighter & Survivor : braincancer

Hi all, we have a podcast called Making Headway that is meant as a support for brain injury survivors. My co-host, Eryn, and I...

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...

Recent Comments